E-drug: Old drug is found to have wide benefits (cont)
---------------------------------------------
Dear Colleagues and moderator,
As to the NYT article on ramipril: In the first place this is not really
new. In the second place somebody has broken the Ingelfinger rule -
so PLEASE let's wait until it is published and we all can discuss and
analyze the results. In the third place: As long as we do not really
know whether this is a cluster effect or particular to ramipril let's wait
and see. E-Drug to my opinion is not a promotional forum, and we
should not have this kind of discussion here. Ramipril came quite late on
the ACE inhibitor market and the manufacturer has done everything he could
to find a niche for the drug: Undercutting prices, discovering "new"
indications etc. Other ACE inhibitors like enalapril are since long
standard treatment in heart failure and there are excellent large-scale
studies to prove that it is much more effective treatment than cardiac
glycosides.
The effectiveness of beta-blockers in heart failure has something to do
with their degree of ISA. Bucindolol apparently has a high degree of ISA,
but I do not know where it is available, and I am curious about negative
studies published about this drug, because I cannot find them. Anyhow, it
is a bad example.
So, please stop this misleading discussion before E-Drug turns into
chaos.
Kind regards,
Dr.L.Offerhaus
Koedijklaan 1a, NL-1406KW Bussum, The Netherlands
Phone: +31-35-6923288. Fax: +31-35-6923290
E-mail: LO@EURONET.NL CompuServe: 71530,15
Eur J Clin Pharmacol ONLY:
POB 75552, NL-1070AN Amsterdam, The Netherlands
[Thanks Leo. I thought perhaps any findings might apply to all 'prils'. A
Critical Assessment of ACE Inhibitors undertaken (a few years ago) on
behalf of the Victorian Drug Usage Advisor Commmittee determined little
difference between ACE inhibitors. To discuss the Critical Assessment,
people could contact "Mary Hemming" <mhemming@tg.com.au> .
Anyway the discussion can be closed. BS. co-moderator.]
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.